Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Aberrant Crypt Foci
B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P.
Acidosis
Hypercapnic acidosis confers antioxidant and anti-apoptosis effects against ventilator-induced lung injury.
Acquired Immunodeficiency Syndrome
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Acute Kidney Injury
Important role of apoptosis signal-regulating kinase 1 in ischemic acute kidney injury.
Acute Kidney Injury
MAP3K kinases and kidney injury.
Acute Kidney Injury
Necroptosis in 3-chloro-1, 2-propanediol (3-MCPD)-dipalmitate-induced acute kidney injury in vivo and its repression by miR-223-3p.
Acute Lung Injury
Mitogen-activated protein kinase kinase kinase 1 protects against nickel-induced acute lung injury.
Acute Lung Injury
SOCS-1 rescues IL-1?-mediated suppression of epithelial sodium channel in mouse lung epithelial cells via ASK-1.
Adenocarcinoma
Apoptosis Signal-Regulating Kinase 1 (ASK1) Activation is Involved in Silver Nanoparticles Induced Apoptosis of A549 Lung Cancer Cell Line.
Adenocarcinoma
Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer.
Adenocarcinoma
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.
Adenocarcinoma
Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.
Adenocarcinoma
Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor.
Adenocarcinoma
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas.
Adenocarcinoma
Cisplatin-resistance involves the defective processing of MEKK1 in human ovarian adenocarcinoma 2008/C13 cells.
Adenocarcinoma
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Adenocarcinoma
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Adenocarcinoma
Differentially expressed genes associated with mouse lung tumor progression.
Adenocarcinoma
ERK/pERK expression, B-raf and K-ras mutations in colon adenocarcinomas: correlation with clinicopathological characteristics and expression of hMLH1 and hMSH2.
Adenocarcinoma
Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients.
Adenocarcinoma
Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression.
Adenocarcinoma
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Adenocarcinoma
Molecular diagnostic testing as an adjunct to morphologic evaluation of pancreatic ductal system brushings: potential augmentation for diagnostic sensitivity.
Adenocarcinoma
Molecular pathology of lung cancer: current status and perspectives.
Adenocarcinoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Adenocarcinoma
Permanent conversion of NIH3T3 cells transformed by activated c-Ha-ras, c-Ki-ras, N-ras, or c-raf, and of human pancreatic adenocarcinoma containing activated c-Ki-ras to apparently normal cells by treatment with the antibiotic azatyrosine.
Adenocarcinoma
Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma.
Adenocarcinoma
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Adenocarcinoma
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.
Adenocarcinoma
Role of the ASK1-SEK1-JNK1-HIPK1 signal in Daxx trafficking and ASK1 oligomerization.
Adenocarcinoma
The role of MEKK1 in hypertrophic cardiomyopathy.
Adenocarcinoma
[Ap1-like cis-elements in 5'-regulatory region of human apolipoprotein A-I gene]
Adenocarcinoma of Lung
A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.
Adenocarcinoma of Lung
A Cross-Platform Comparison of Genome-Wide Expression Changes of Laser Microdissected Lung Tissue of C-Raf Transgenic Mice Using 3'IVT and Exon Array.
Adenocarcinoma of Lung
Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
Adenocarcinoma of Lung
Apoptosis signal-regulating kinase 1 mediates denbinobin-induced apoptosis in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Adenocarcinoma of Lung
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population.
Adenocarcinoma of Lung
Molecular alterations in non-small cell lung carcinomas of the young.
Adenocarcinoma of Lung
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Adenocarcinoma of Lung
Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
Adenocarcinoma of Lung
Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers.
Adenoma
B-RAF mutations are a rare event in pituitary adenomas.
Adenoma
BAG-1 haplo-insufficiency impairs lung tumorigenesis.
Adenoma
Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1.
Adenoma
Differentially expressed genes associated with mouse lung tumor progression.
Adenoma
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Adenoma
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Adenoma
No rearrangement of c-mos in salivary gland pleomorphic adenomas with 8q12 aberrations.
Adenoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Adenoma
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.
Adenoma
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Adenoma
Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.
Adenoma
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Adenoma, Bile Duct
Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
Adenoma, Liver Cell
Infrequent activation of K-ras, H-ras, and other oncogenes in hepatocellular neoplasms initiated by methyl(acetoxymethyl)nitrosamine, a methylating agent, and promoted by phenobarbital in F344 rats.
Adenoma, Pleomorphic
No rearrangement of c-mos in salivary gland pleomorphic adenomas with 8q12 aberrations.
Adenoma, Pleomorphic
Structural alterations of the c-mos locus in benign pleomorphic adenomas with chromosome abnormalities of 8q12.
Adenomatous Polyposis Coli
Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Adenomatous Polyposis Coli
Colon Cancer: A Clinician's Perspective in 2019.
Adenomatous Polyposis Coli
Differential molecular assemblies underlie the dual function of Axin in modulating the WNT and JNK pathways.
Adenomatous Polyposis Coli
Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer.
Adenoviridae Infections
Adenovirus E1B 19,000-molecular-weight protein activates c-Jun N-terminal kinase and c-Jun-mediated transcription.
Adrenocortical Carcinoma
Regulation of stimulus-induced interleukin-8 gene transcription in human adrenocortical carcinoma cells - Role of AP-1 and NF-?B.
Alopecia
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Ameloblastoma
Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
Angiomyolipoma
The role of tuberin in cellular differentiation: are B-raf and MAPK involved?
Anthrax
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Anthrax
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
aromatase deficiency
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Arthralgia
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Arthritis
c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 is a critical regulator for arthritis progression by meditating inflammation in mice model.
Arthritis
Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis.
Arthritis
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Arthritis
The effect of apoptosis signal-regulating kinase 1 gene transfer on rat collagen induced arthritis.
Arthritis, Experimental
c-Jun NH2-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 is a critical regulator for arthritis progression by meditating inflammation in mice model.
Arthritis, Experimental
Necrostatin-1 ameliorates adjuvant arthritis rat articular chondrocyte injury via inhibiting ASIC1a-mediated necroptosis.
Arthritis, Experimental
Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice.
Arthritis, Rheumatoid
Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis.
Arthritis, Rheumatoid
Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.
Arthritis, Rheumatoid
Gene-gene interaction and RNA splicing profiles of MAP2K4 gene in rheumatoid arthritis.
Arthritis, Rheumatoid
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients.
Arthritis, Rheumatoid
K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis.
Arthritis, Rheumatoid
MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Regulation and function of apoptosis signal-regulating kinase 1 in rheumatoid arthritis.
Arthritis, Rheumatoid
Regulation and function of TPL-2, an I?B kinase-regulated MAP kinase kinase kinase.
Arthritis, Rheumatoid
Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.
Astrocytoma
A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas.
Astrocytoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Astrocytoma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Astrocytoma
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas.
Astrocytoma
Differential effects of cAMP in neurons and astrocytes. Role of B-raf.
Astrocytoma
Genetic recombination in human melanoma and astrocytoma cell lines involves oncogenes and growth factor genes.
Ataxia Telangiectasia
DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy.
Ataxia Telangiectasia
Racial Disparities in the Molecular Landscape of Cancer.
Atherosclerosis
A Novel ASK Inhibitor AGI-1067 Inhibits TLR-4-Mediated Activation of ASK1 by Preventing Dissociation of Thioredoxin from ASK1.
Atherosclerosis
A20 functions as mediator in TNF?-induced injury of human umbilical vein endothelial cells through TAK1-dependent MAPK/eNOS pathway.
Atherosclerosis
Critical and diverse in vivo roles of apoptosis signal-regulating kinase 1 in animal models of atherosclerosis and cholestatic liver injury.
Atherosclerosis
Endothelial MAP4K4 is critical for lymphatic vascular development and function.
Atherosclerosis
Evidence for markers of hypoxia and apoptosis in explanted human carotid atherosclerotic plaques.
Atherosclerosis
Identification of hypo- and hypermethylated genes related to atherosclerosis by a genome-wide analysis of DNA methylation.
Atherosclerosis
Map4k4 impairs energy metabolism in endothelial cells and promotes insulin resistance in obesity.
Bacterial Infections
MEKK3 Regulates IFN-{gamma} Production in T Cells through the Rac1/2-Dependent MAPK Cascades.
Brain Infarction
Regulation of Microglia and Macrophage Polarization via Apoptosis Signal-Regulating Kinase 1 Silencing after Ischemic/Hypoxic Injury.
Brain Injuries
Apoptosis signal-regulating kinase 1 (ASK1) is linked to neural stem cell differentiation after ischemic brain injury.
Brain Injuries
Dual inhibitory roles of geldanamycin on the c-Jun NH(2)-terminal kinase 3 signal pathway through suppressing the expression of mixed-lineage kinase 3 and attenuating the activation of apoptosis signal-regulating kinase 1 via facilitating the activation of Akt in ischemic brain injury.
Brain Injuries
Excess salt causes cerebral neuronal apoptosis and inflammation in stroke-prone hypertensive rats through angiotensin II-induced NADPH oxidase activation.
Brain Injuries
Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
Brain Injuries
The degradation of mixed lineage kinase domain-like protein promotes neuroprotection after ischemic brain injury.
Brain Injuries
Transforming Growth Factor Beta-Activated Kinase 1-Dependent Microglial and Macrophage Responses Aggravate Long-Term Outcomes After Ischemic Stroke.
Brain Injuries, Traumatic
Inhibition of transforming growth factor beta-activated kinase 1 confers neuroprotection after traumatic brain injury in rats.
Brain Ischemia
Activation and autophosphorylation of apoptosis signal-regulating kinase 1 (ASK1) following cerebral ischemia in rat hippocampus.
Brain Ischemia
Antioxidant N-acetylcysteine inhibits the activation of JNK3 mediated by the GluR6-PSD95-MLK3 signaling module during cerebral ischemia in rat hippocampus.
Brain Ischemia
Biphasic activation of apoptosis signal-regulating kinase 1-stress-activated protein kinase 1-c-Jun N-terminal protein kinase pathway is selectively mediated by Ca2+-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors involving oxidative stress following brain ischemia in rat hippocampus.
Brain Ischemia
Blockade of Apoptosis Signal-Regulating Kinase 1 Attenuates Matrix Metalloproteinase 9 Activity in Brain Endothelial Cells and the Subsequent Apoptosis in Neurons after Ischemic Injury.
Brain Ischemia
Brain-targeting delivery for RNAi neuroprotection against cerebral ischemia reperfusion injury.
Brain Ischemia
Cell Type-Specific Mechanisms in the Pathogenesis of Ischemic Stroke: The Role of Apoptosis Signal-Regulating Kinase 1.
Brain Ischemia
Heat shock proteins in the brain: role of Hsp70, Hsp 27, and HO-1 (Hsp32) and their therapeutic potential.
Brain Ischemia
Post-ischemic salubrinal administration reduces necroptosis in a rat model of global cerebral ischemia.
Brain Ischemia
Regulation of Microglia and Macrophage Polarization via Apoptosis Signal-Regulating Kinase 1 Silencing after Ischemic/Hypoxic Injury.
Brain Ischemia
S-nitrosylation of mixed lineage kinase 3 contributes to its activation after cerebral ischemia.
Brain Neoplasms
JSAP1/JIP3 cooperates with focal adhesion kinase to regulate c-Jun N-terminal kinase and cell migration.
Brain Neoplasms
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Brain Neoplasms
PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells.
Breast Neoplasms
A cis and trans adenine-dependent hairpin ribozyme against Tpl-2 target.
Breast Neoplasms
A MAP3k1 SNP predicts survival of gastric cancer in a Chinese population.
Breast Neoplasms
A Short Hairpin DNA Analogous to miR-125b Inhibits C-Raf Expression, Proliferation, and Survival of Breast Cancer Cells.
Breast Neoplasms
A single point mutation responsible for c-mos polymorphism in cancer patients.
Breast Neoplasms
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Breast Neoplasms
Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
Breast Neoplasms
Apoptosis signal-regulating kinase 1 is associated with the effect of claudin-6 in breast cancer.
Breast Neoplasms
Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies.
Breast Neoplasms
Association between Mitogen-Activated Protein Kinase Kinase Kinase 1 Polymorphisms and Breast Cancer Susceptibility: A Meta-Analysis of 20 Case-Control Studies.
Breast Neoplasms
Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Breast Neoplasms
Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
Breast Neoplasms
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
Breast Neoplasms
Bag-1 stimulates Bad phosphorylation through activation of Akt and Raf kinases to mediate cell survival in breast cancer.
Breast Neoplasms
BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
Breast Neoplasms
Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
Breast Neoplasms
Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.
Breast Neoplasms
Breast cancer susceptibility variants alter risks in familial disease.
Breast Neoplasms
Breast cancer susceptibility: current knowledge and implications for genetic counselling.
Breast Neoplasms
c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Breast Neoplasms
Calcitonin targets extracellular signal-regulated kinase signaling pathway in human cancers.
Breast Neoplasms
CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Breast Neoplasms
Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases.
Breast Neoplasms
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Breast Neoplasms
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Breast Neoplasms
Computational algorithms for in silico profiling of activating mutations in cancer.
Breast Neoplasms
Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes.
Breast Neoplasms
Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women.
Breast Neoplasms
Dominant-negative Jun N-terminal protein kinase (JNK-1) inhibits metabolic oxidative stress during glucose deprivation in a human breast carcinoma cell line.
Breast Neoplasms
Erufosine suppresses breast cancer in vitro and in vivo for its activity on PI3K, c-Raf and Akt proteins.
Breast Neoplasms
Estrogen suppresses MLK3-mediated apoptosis sensitivity in ER+ breast cancer cells.
Breast Neoplasms
Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.
Breast Neoplasms
Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Breast Neoplasms
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Breast Neoplasms
Genetic susceptibility loci for breast cancer by estrogen receptor status.
Breast Neoplasms
Genetic variants in FGFR2 and MAP3K1 are associated with the risk of familial and early-onset breast cancer in a South-American population.
Breast Neoplasms
Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.
Breast Neoplasms
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
Breast Neoplasms
Hormone-related pathways and risk of breast cancer subtypes in African American women.
Breast Neoplasms
Human Epidermal Growth Factor Receptor 2 (HER2) Impedes MLK3 Kinase Activity to Support Breast Cancer Cell Survival.
Breast Neoplasms
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Breast Neoplasms
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk.
Breast Neoplasms
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.
Breast Neoplasms
Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity.
Breast Neoplasms
Investigating the therapeutic potential and mechanism of curcumin in breast cancer based on RNA sequencing and bioinformatics analysis.
Breast Neoplasms
Knockdown of apoptosis signal-regulating kinase 1 modulates basal glycogen synthase kinase-3? kinase activity and regulates cell migration.
Breast Neoplasms
Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Breast Neoplasms
MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.
Breast Neoplasms
MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis.
Breast Neoplasms
MEK-ERK signaling controls Hdm2 oncoprotein expression by regulating hdm2 mRNA export to the cytoplasm.
Breast Neoplasms
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Breast Neoplasms
MEKK1/JNK signaling stabilizes and activates p53.
Breast Neoplasms
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Breast Neoplasms
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.
Breast Neoplasms
Miconazole triggers various forms of cell death in human breast cancer MDA-MB-231 cells.
Breast Neoplasms
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Breast Neoplasms
MicroRNA-143 inhibits cell growth by targeting ERK5 and MAP3K7 in breast cancer.
Breast Neoplasms
MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
Breast Neoplasms
Non-Benzoquinone Geldanamycin Analog, WK-88-1, Induces Apoptosis in Human Breast Cancer Cell Lines.
Breast Neoplasms
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Breast Neoplasms
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Breast Neoplasms
Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.
Breast Neoplasms
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Breast Neoplasms
Platycodin d induces reactive oxygen species-mediated apoptosis signal-regulating kinase 1 activation and endoplasmic reticulum stress response in human breast cancer cells.
Breast Neoplasms
Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.
Breast Neoplasms
Predictive accuracy of the breast cancer genetic risk model based on eight common genetic variants: The BACkSIDE study.
Breast Neoplasms
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients.
Breast Neoplasms
Replication of breast cancer susceptibility loci in whites and African Americans using a Bayesian approach.
Breast Neoplasms
Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-Hispanic white women living in the Southwestern United States.
Breast Neoplasms
Risk of genome-wide association study newly identified genetic variants for breast cancer in Chinese women of Heilongjiang Province.
Breast Neoplasms
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Breast Neoplasms
RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-?B.
Breast Neoplasms
Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.
Breast Neoplasms
The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.
Breast Neoplasms
Topological alternate centrality measure capturing drug targets in the network of MAPK pathways.
Breast Neoplasms
Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.
Breast Neoplasms
Two-dimensional electrophoretic analysis of human breast carcinoma proteins: mapping of proteins that bind to the SH3 domain of mixed lineage kinase MLK2.
Breast Neoplasms
[Genetic polymorphism and susceptibility to cancer]
Breast Neoplasms
[Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]
Burkitt Lymphoma
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
Carcinogenesis
A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
Carcinogenesis
A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.
Carcinogenesis
A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1.
Carcinogenesis
Apoptosis signal-regulating kinase 1 and cyclin D1 compose a positive feedback loop contributing to tumor growth in gastric cancer.
Carcinogenesis
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Carcinogenesis
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Carcinogenesis
B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells.
Carcinogenesis
B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Carcinogenesis
B-RAF mutations are a rare event in pituitary adenomas.
Carcinogenesis
C-raf expression in early rat liver tumorigenesis after promotion with polychlorinated biphenyls or phenobarbital.
Carcinogenesis
C-Raf is required for the initiation of lung cancer by K-Ras.
Carcinogenesis
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Carcinogenesis
Correction: Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Carcinogenesis
Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Carcinogenesis
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Carcinogenesis
Differential roles of ASK1 and TAK1 in Helicobacter pylori-induced cellular responses.
Carcinogenesis
Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Carcinogenesis
Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Carcinogenesis
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Carcinogenesis
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Carcinogenesis
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development.
Carcinogenesis
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Carcinogenesis
Expression of B-RAF V600E in type II pneumocytes causes abnormalities in alveolar formation, airspace enlargement and tumor formation in mice.
Carcinogenesis
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis.
Carcinogenesis
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Carcinogenesis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Carcinogenesis
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Carcinogenesis
HCC Specific Protein Network Involving Interactions of EGFR with A-Raf and Transthyretin: Experimental Analysis and Computational Biology Correlates.
Carcinogenesis
hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in inflammation.
Carcinogenesis
Identification, by cDNA microarray, of A-raf and proliferating cell nuclear antigen as genes induced in rat lung by exposure to diesel exhaust.
Carcinogenesis
Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in LSL-KrasG12D/Pdx-1-Cre Mice.
Carcinogenesis
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Carcinogenesis
Lin9, a subunit of the mammalian DREAM complex, is essential for embryonic development, for survival of adult mice and for tumor suppression.
Carcinogenesis
Loss of BRCA1 Spontaneously Induces the Tumorigenesis in Lacrimal Gland.
Carcinogenesis
Mammary cancer promotion and MAPK activation associated with consumption of a corn oil-based high-fat diet.
Carcinogenesis
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Carcinogenesis
Mitogen-activated protein 3 kinase 6 mediates angiogenic and tumorigenic effects via vascular endothelial growth factor expression.
Carcinogenesis
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Carcinogenesis
Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1.
Carcinogenesis
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis.
Carcinogenesis
MLK3 silence induces cervical cancer cell apoptosis via the Notch-1/autophagy network.
Carcinogenesis
Molecular alterations in non-small cell lung carcinomas of the young.
Carcinogenesis
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Carcinogenesis
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Carcinogenesis
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Carcinogenesis
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Carcinogenesis
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signaling.
Carcinogenesis
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Carcinogenesis
p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.
Carcinogenesis
RAF expression in human astrocytic tumors.
Carcinogenesis
RanBPM is an inhibitor of ERK signaling.
Carcinogenesis
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Carcinogenesis
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
Carcinogenesis
Revealing A-Raf functions through its interactome.
Carcinogenesis
Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK.
Carcinogenesis
Structural investigation of B-raf paradox breaker and inducer inhibitors.
Carcinogenesis
TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.
Carcinogenesis
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
Carcinogenesis
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
Carcinogenesis
The BRAF mutation is associated with the prognosis in colorectal cancer.
Carcinogenesis
The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines.
Carcinogenesis
Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.
Carcinogenesis
Tumorigenesis suppressor pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Carcinogenesis
[CNC proteins in physiology and pathology].
Carcinogenesis
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinogenesis
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Carcinoid Tumor
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Carcinoma
A single point mutation responsible for c-mos polymorphism in cancer patients.
Carcinoma
Abrogation of c-Raf expression induces apoptosis in tumor cells.
Carcinoma
Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
Carcinoma
Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.
Carcinoma
Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Carcinoma
Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells.
Carcinoma
ASK1 mediates apoptotic cell death induced by genotoxic stress.
Carcinoma
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Carcinoma
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Carcinoma
B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Carcinoma
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Carcinoma
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Carcinoma
c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Carcinoma
c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.
Carcinoma
Cancer emerging from the recurrence of sessile serrated adenoma/polyp resected endoscopically 5 years ago.
Carcinoma
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Carcinoma
Conditional expression of oncogenic C-RAF in mouse pulmonary epithelial cells reveals differential tumorigenesis and induction of autophagy leading to tumor regression.
Carcinoma
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Carcinoma
Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.
Carcinoma
Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Carcinoma
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Carcinoma
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.
Carcinoma
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Carcinoma
Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.
Carcinoma
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma
Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma.
Carcinoma
Expression of apoptosis signal-regulating kinase 1 is associated with tight junction protein claudin-6 in cervical carcinoma.
Carcinoma
Expression of polysialic acid in primary laryngeal squamous cell carcinoma.
Carcinoma
Expression of ssDNA in mammalian cells.
Carcinoma
Expression of TAK1/TAB1 expression in non-small cell lung carcinoma and adjacent normal tissues and their clinical significance.
Carcinoma
Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation.
Carcinoma
Gene expression in poorly differentiated papillary thyroid carcinomas.
Carcinoma
Genome-Wide Association Studies of Autoimmune Thyroid Diseases, Thyroid Function, and Thyroid Cancer.
Carcinoma
H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma.
Carcinoma
Identification of a negative regulatory element that inhibits c-mos transcription in somatic cells.
Carcinoma
Immunohistochemical localization of c-mos at the light and electron microscope level in non-small cell lung carcinomas.
Carcinoma
Inhibition of mutant Kras(G12D)-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Carcinoma
K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma.
Carcinoma
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Carcinoma
Long non-coding RNA-OIS1 inhibits HPV-positive, but not HPV-negative cervical squamous cell carcinoma by upregulating MTK-1.
Carcinoma
Loss of heterozygosity at the c-raf locus in small cell lung carcinoma.
Carcinoma
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas.
Carcinoma
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Carcinoma
MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
Carcinoma
MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Carcinoma
MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1.
Carcinoma
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
Carcinoma
Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability.
Carcinoma
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Carcinoma
Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma.
Carcinoma
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Carcinoma
Overexpression of the Tpl-2/Cot oncogene in human breast cancer.
Carcinoma
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cells.
Carcinoma
pERK activation in esophageal carcinomas: clinicopathological associations.
Carcinoma
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Carcinoma
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Carcinoma
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
Carcinoma
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Carcinoma
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Carcinoma
Relationship of the K-ras/c-mos expression patterns with angiogenesis in non-small cell lung carcinomas.
Carcinoma
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Carcinoma
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Carcinoma
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma.
Carcinoma
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Carcinoma
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Carcinoma
Tumorigenesis suppressor pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion.
Carcinoma
[Genetic polymorphism and susceptibility to cancer]
Carcinoma
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinoma in Situ
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Carcinoma, Basal Cell
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Carcinoma, Embryonal
Differential expression of protooncogenes in human germ cell tumors of the testis.
Carcinoma, Embryonal
Expression of JNK cascade scaffold protein JSAP1 in the mouse nervous system.
Carcinoma, Embryonal
MEKK4 mediates differentiation in response to retinoic acid via activation of c-Jun N-terminal kinase in rat embryonal carcinoma P19 cells.
Carcinoma, Hepatocellular
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Carcinoma, Hepatocellular
A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.
Carcinoma, Hepatocellular
Activated c-raf gene in a rat hepatocellular carcinoma induced by 2-amino-3-methylimidazo[4,5-f]quinoline.
Carcinoma, Hepatocellular
Activation of rat c-raf during transfection of hepatocellular carcinoma DNA.
Carcinoma, Hepatocellular
Apoptosis signal-regulating kinase 1 inhibits hepatocarcinogenesis by controlling the tumor-suppressing function of stress-activated mitogen-activated protein kinase.
Carcinoma, Hepatocellular
Apoptosis signal-regulating kinase 1 mediates the inhibitory effect of hepatocyte nuclear factor-4? on hepatocellular carcinoma.
Carcinoma, Hepatocellular
B-Raf and MEK inhibitors differentially regulate cell fate and microenvironment in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation.
Carcinoma, Hepatocellular
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Carcinoma, Hepatocellular
Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression.
Carcinoma, Hepatocellular
Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms.
Carcinoma, Hepatocellular
Glycogen synthase kinase-3? antagonizes ROS-induced hepatocellular carcinoma cell death through suppression of the apoptosis signal-regulating kinase 1.
Carcinoma, Hepatocellular
Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.
Carcinoma, Hepatocellular
Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver.
Carcinoma, Hepatocellular
Increased expression of c-jun gene during spontaneous hepatocarcinogenesis in LEC rats.
Carcinoma, Hepatocellular
Interaction of the hepatitis B spliced protein with cathepsin B promotes hepatoma cell migration and invasion.
Carcinoma, Hepatocellular
Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf.
Carcinoma, Hepatocellular
MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MicroRNA-520b inhibits growth of hepatoma cells by targeting MEKK2 and cyclin D1.
Carcinoma, Hepatocellular
Mixed lineage kinase 3 (MLK3)-activated p38 MAP kinase mediates transforming growth factor-beta-induced apoptosis in hepatoma cells.
Carcinoma, Hepatocellular
Molecular mechanisms governing microRNA-125a expression in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Mouse hepatomas with Ha-ras and B-raf mutations differ in mitogen-activated protein kinase signaling and response to constitutive androstane receptor activation.
Carcinoma, Hepatocellular
Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma, Hepatocellular
Rat c-raf oncogene is located on chromosome 4 and may be activated by sequences from chromosome 13.
Carcinoma, Hepatocellular
RNA interference may be more potent than antisense RNA in human cancer cell lines.
Carcinoma, Hepatocellular
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Hepatocellular
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
Carcinoma, Hepatocellular
Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway.
Carcinoma, Hepatocellular
[A study on expression of various oncogenes and tumor-associated genes in LEC rats spontaneously developing hepatitis and hepatoma]
Carcinoma, Large Cell
Cooperation of c-raf-1 and c-myc protooncogenes in the neoplastic transformation of simian virus 40 large tumor antigen-immortalized human bronchial epithelial cells.
Carcinoma, Medullary
Targeted therapy: A new hope for thyroid carcinomas.
Carcinoma, Non-Small-Cell Lung
B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up.
Carcinoma, Non-Small-Cell Lung
miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Multiple primary malignant neoplasms: A case report and literature review.
Carcinoma, Non-Small-Cell Lung
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Carcinoma, Non-Small-Cell Lung
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Non-Small-Cell Lung
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Carcinoma, Non-Small-Cell Lung
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Carcinoma, Papillary
B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules.
Carcinoma, Papillary
BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products.
Carcinoma, Papillary
High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
Carcinoma, Papillary
New molecular targeted therapies in thyroid cancer.
Carcinoma, Papillary
Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule.
Carcinoma, Renal Cell
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Carcinoma, Renal Cell
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Carcinoma, Renal Cell
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Carcinoma, Renal Cell
Fas-induced apoptosis of renal cell carcinoma is mediated by apoptosis signal-regulating kinase 1 via mitochondrial damage-dependent caspase-8 activation.
Carcinoma, Renal Cell
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Carcinoma, Renal Cell
MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.
Carcinoma, Renal Cell
Population Pharmacokinetic Analysis of Sorafenib in Patients with Solid Tumors.
Carcinoma, Renal Cell
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Carcinoma, Renal Cell
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Carcinoma, Renal Cell
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Carcinoma, Renal Cell
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma.
Carcinoma, Squamous Cell
Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: implication in drug and radioresistance.
Carcinoma, Squamous Cell
Expression of polysialic acid in primary laryngeal squamous cell carcinoma.
Carcinoma, Squamous Cell
Lack of B-RAF mutations in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Long non-coding RNA-OIS1 inhibits HPV-positive, but not HPV-negative cervical squamous cell carcinoma by upregulating MTK-1.
Carcinoma, Squamous Cell
pERK activation in esophageal carcinomas: clinicopathological associations.
Carcinoma, Squamous Cell
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Cardio-Renal Syndrome
Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome.
Cardiomegaly
A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy.
Cardiomegaly
Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome.
Cardiomegaly
Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Cardiomegaly
Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
Cardiomegaly
Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy.
Cardiomegaly
MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.
Cardiomegaly
Novel mechanism of angiotensin II-induced cardiac injury in hypertensive rats: the critical role of ASK1 and VEGF.
Cardiomegaly
Oligomerized grape seed proanthocyanidins ameliorates isoproterenol-induced cardiac remodeling in rats: role of oxidative stress.
Cardiomegaly
Regulator of G Protein Signaling 6 Facilities Cardiac Hypertrophy by Activating Apoptosis Signal-Regulating Kinase 1-P38/c-JUN N-Terminal Kinase 1/2 Signaling.
Cardiomegaly
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.
Cardiomegaly
The role of MEKK1 in hypertrophic cardiomyopathy.
Cardiomegaly
Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase.
Cardiomyopathy, Dilated
Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer.
Cardiomyopathy, Hypertrophic
The role of MEKK1 in hypertrophic cardiomyopathy.
Cardiovascular Diseases
Crystal structures of ASK1-inhibtor complexes provide a platform for structure-based drug design.
Cardiovascular Diseases
Identification of novel ASK1 inhibitors using virtual screening.
Catalepsy
Map3k1, Il6st, Gzmk, and Hspb3 gene coexpression network in the mechanism of freezing reaction in mice.
Cell Transformation, Neoplastic
A novel role for mixed-lineage kinase-like mitogen-activated protein triple kinase alpha in neoplastic cell transformation and tumor development.
Cerebral Hemorrhage
MEKK1 Associated with Neuronal Apoptosis Following Intracerebral Hemorrhage.
Cerebral Infarction
Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.
Cholangiocarcinoma
Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes.
Cholangiocarcinoma
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Cholangiocarcinoma
Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
Cholangiocarcinoma
The MAPK Kinase Kinase 4 Deficiency in Intrahepatic Cholangiocarcinoma Leads to Invasive Growth and Epithelial-Mesenchymal Transition.
Cholangiocarcinoma
[Molecular genetic approaches in parasitology (in case of opisthorchiasis)]
Chondrosarcoma
Apoptosis signal-regulating kinase 1 is involved in brain-derived neurotrophic factor (BDNF)-enhanced cell motility and matrix metalloproteinase 1 expression in human chondrosarcoma cells.
Chondrosarcoma
Epigallocatechin-3-gallate induces cell apoptosis of human chondrosarcoma cells through apoptosis signal-regulating kinase 1 pathway.
Chondrosarcoma
FPipTB, a benzimidazole derivative, induces chondrosarcoma cell apoptosis via endoplasmic reticulum stress and apoptosis signal-regulating kinase 1.
Choriocarcinoma
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Choriocarcinoma
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole.
Choriocarcinoma
Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study.
Chronic Periodontitis
Loss of periodontal ligament fibroblasts by RIPK3-MLKL-mediated necroptosis in the progress of chronic periodontitis.
Colitis
ABIN-2, of the TPL-2 Signaling Complex, Modulates Mammalian Inflammation.
Colitis
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Colitis
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Colitis, Ulcerative
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.
Colitis, Ulcerative
Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages.
Colitis, Ulcerative
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Colonic Diseases
Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses.
Colonic Neoplasms
A LIN28B polymorphism predicts for colon cancer survival.
Colonic Neoplasms
Activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin-induced apoptosis of colon cancer cells.
Colonic Neoplasms
Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.
Colonic Neoplasms
Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer.
Colonic Neoplasms
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
Colonic Neoplasms
Cationic liposome co-encapsulation of SMAC mimetic and zVAD using a novel lipid bilayer fusion loaded with MLKL-pDNA for tumour inhibition in vivo.
Colonic Neoplasms
Colon Cancer: A Clinician's Perspective in 2019.
Colonic Neoplasms
Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells.
Colonic Neoplasms
Comparative mutational analysis of distal colon cancer with rectal cancer.
Colonic Neoplasms
ERK/pERK expression, B-raf and K-ras mutations in colon adenocarcinomas: correlation with clinicopathological characteristics and expression of hMLH1 and hMSH2.
Colonic Neoplasms
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
Colonic Neoplasms
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Colonic Neoplasms
RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors.
Colonic Neoplasms
Suppression of serum-induced c-jun expression by activated Ki-ras in human colon cancer cells.
Colonic Neoplasms
Tumor necrosis factor-related genes and colon and rectal cancer.
Colorectal Neoplasms
5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Colorectal Neoplasms
A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers.
Colorectal Neoplasms
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Colorectal Neoplasms
Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer.
Colorectal Neoplasms
Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab.
Colorectal Neoplasms
Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients.
Colorectal Neoplasms
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
Colorectal Neoplasms
B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Colorectal Neoplasms
B-Raf mutation: a key player in molecular biology of cancer.
Colorectal Neoplasms
BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Colorectal Neoplasms
Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
Colorectal Neoplasms
Concomitant RAS and BRAF mutation in colorectal cancer - A report of 7 cases.
Colorectal Neoplasms
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Colorectal Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Colorectal Neoplasms
Differences in symptom occurrence, severity, and distress ratings between patients with gastrointestinal cancers who received chemotherapy alone or chemotherapy with targeted therapy.
Colorectal Neoplasms
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Colorectal Neoplasms
Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Colorectal Neoplasms
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Colorectal Neoplasms
Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
Colorectal Neoplasms
Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines.
Colorectal Neoplasms
Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
Colorectal Neoplasms
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Colorectal Neoplasms
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Colorectal Neoplasms
Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma.
Colorectal Neoplasms
K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues.
Colorectal Neoplasms
KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Colorectal Neoplasms
MAP3K1 functionally interacts with Axin1 in the canonical Wnt signalling pathway.
Colorectal Neoplasms
MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights.
Colorectal Neoplasms
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Colorectal Neoplasms
Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis.
Colorectal Neoplasms
MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells.
Colorectal Neoplasms
Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer.
Colorectal Neoplasms
MTDH and MAP3K1 are direct targets of apoptosis-regulating miRNAs in colorectal carcinoma.
Colorectal Neoplasms
mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.
Colorectal Neoplasms
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Colorectal Neoplasms
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Colorectal Neoplasms
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.
Colorectal Neoplasms
Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Colorectal Neoplasms
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Colorectal Neoplasms
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Colorectal Neoplasms
RAF protein-serine/threonine kinases: structure and regulation.
Colorectal Neoplasms
Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf.
Colorectal Neoplasms
Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis.
Colorectal Neoplasms
TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status.
Colorectal Neoplasms
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.
Colorectal Neoplasms
The BRAF mutation is associated with the prognosis in colorectal cancer.
Colorectal Neoplasms
The MAP3K ZAK, a novel modulator of ERK-dependent migration, is upregulated in colorectal cancer.
Colorectal Neoplasms
The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Colorectal Neoplasms
Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
Colorectal Neoplasms
[Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]
Colorectal Neoplasms
[Correlation of K-ras Gene Mutations with the Protein Expressions of TAK1 and MAP4K2 in Colorectal Cancer].
Colorectal Neoplasms
[The RAS paradoxon of the EGFR-targeted therapy of colorectal cancer]
Confusion
Isoforms of JSAP1 scaffold protein generated through alternative splicing.
Congenital Disorders of Glycosylation
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Crohn Disease
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
Crohn Disease
MEKK4 sequesters RIP2 to dictate NOD2 signal specificity.
Crohn Disease
Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease.
Cutis Laxa
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Cystadenoma
[Serous genital carcinoma : Molecular pathogenesis and the role of tubal fimbria.]
Cysts
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Cysts
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Cysts
Cyst formation in kidney via B-Raf signaling in the PKD2 transgenic mice.
Cysts
Glycomolecules in Echinococcus granulosus cyst fluid inhibit TLR4-mediated inflammatory responses via c-Raf.
Cysts
Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: a systems biology approach.
Cysts
Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
Cysts
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Deafness
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Dehydration
A gene encoding a mitogen-activated protein kinase kinase kinase is induced simultaneously with genes for a mitogen-activated protein kinase and an S6 ribosomal protein kinase by touch, cold, and water stress in Arabidopsis thaliana.
Demyelinating Diseases
RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation.
Dendritic Cell Sarcoma, Interdigitating
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.
Dental Caries
A new species of the genus Rhabdophis Fitzinger, 1843 (Squamata: Colubridae) from Guangdong Province, southern China.
Dermatitis, Phototoxic
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Diabetes Mellitus
Association of Common Genetic Variants in Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 with Type 2 Diabetes Mellitus in a Chinese Han Population.
Diabetes Mellitus
Inhibition of MafA transcriptional activity and human insulin gene transcription by interleukin-1beta and mitogen-activated protein kinase kinase kinase in pancreatic islet beta cells.
Diabetes Mellitus
MAP3K1 May be a Promising Susceptibility Gene for Type 2 Diabetes Mellitus in an Iranian Population.
Diabetes Mellitus
The Rap-B-Raf signalling pathway is activated by glucose and glucagon-like peptide-1 in human islet cells.
Diabetes Mellitus, Type 2
Association of Common Genetic Variants in Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 with Type 2 Diabetes Mellitus in a Chinese Han Population.
Diabetes Mellitus, Type 2
Identification of apoptosis signal-regulating kinase 1 (ASK1) inhibitors among the derivatives of benzothiazol-2-yl-3-hydroxy-5-phenyl-1,5-dihydro-pyrrol-2-one.
Diabetes Mellitus, Type 2
MAP3K1 May be a Promising Susceptibility Gene for Type 2 Diabetes Mellitus in an Iranian Population.
Diabetic Cardiomyopathies
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
Diabetic Nephropathies
ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice.
Diabetic Nephropathies
Cyclin-dependent kinase 5 contributes to endoplasmic reticulum stress induced podocyte apoptosis via promoting MEKK1 phosphorylation at Ser280 in diabetic nephropathy.
Diabetic Nephropathies
High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway.
Diastema
A new species of the genus Rhabdophis Fitzinger, 1843 (Squamata: Colubridae) from Guangdong Province, southern China.
dihydropyrimidinase deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Dihydropyrimidine Dehydrogenase Deficiency
Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: A systemic review of current development, evidence, and recommendation.
Disorders of Sex Development
Minor abnormalities of testis development in mice lacking the gene encoding the MAPK signalling component, MAP3K1.
Disorders of Sex Development
Mutation analysis of mitogen activated protein kinase 1 gene in Indian cases of 46,XY disorder of sex development.
Disorders of Sex Development
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination.
Disorders of Sex Development
Mutations in MAP3K1 that cause 46,XY disorders of sex development disrupt distinct structural domains in the protein.
Encephalitis
Mechanisms of minocycline-induced suppression of simian immunodeficiency virus encephalitis: inhibition of apoptosis signal-regulating kinase 1.
Encephalomyelitis
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Encephalomyelitis, Autoimmune, Experimental
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Endocrine Gland Neoplasms
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Endometrial Neoplasms
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Endometriosis
Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis.
Endotoxemia
GSK-3?-induced ASK1 stabilization is crucial in LPS-induced endotoxin shock.
Enterocolitis, Necrotizing
Tumor necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during necrotizing enterocolitis.
Eosinophilia
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Epilepsy
The inhibition of transforming growth factor beta-activated kinase 1 contributed to neuroprotection via inflammatory reaction in pilocarpine-induced rats with epilepsy.
Esophageal Neoplasms
Griffipavixanthone, a dimeric xanthone extracted from edible plants, inhibits tumor metastasis and proliferation via downregulation of the RAF pathway in esophageal cancer.
Esophageal Neoplasms
Presence of an EcoRI RFLP of the c-mos locus in normal and tumor tissue of esophageal cancer patients.
Esophageal Squamous Cell Carcinoma
K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma.
Exanthema
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Eye Manifestations
MEK kinase 1 regulates c-Jun phosphorylation in the control of corneal morphogenesis.
Fanconi Anemia
Enhanced TNF-alpha-induced apoptosis in Fanconi anemia type C-deficient cells is dependent on apoptosis signal-regulating kinase 1.
Fatty Liver
Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Fatty Liver
Discovery of potent apoptosis signal-regulating kinase 1 inhibitors via integrated computational strategy and biological evaluation.
Fatty Liver
Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis.
Fatty Liver
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Fibrosarcoma
Depletion of RIPK3 or MLKL blocks TNF-driven necroptosis and switches towards a delayed RIPK1 kinase-dependent apoptosis.
Fibrosarcoma
Inhibition of apoptosis signal-regulating kinase 1 by nitric oxide through a thiol redox mechanism.
Fibrosarcoma
Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1.
Ganglioglioma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Ganglion Cysts
Up-regulation of Ras/Raf/ERK1/2 signaling in the spinal cord impairs neural cell migration, neurogenesis, synapse formation, and dendritic spine development.
Gastrointestinal Stromal Tumors
Multiple primary malignant neoplasms: A case report and literature review.
Genetic Diseases, Inborn
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development.
Gestational Trophoblastic Disease
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Glaucoma
Dock3-NMDA receptor interaction as a target for glaucoma therapy.
Glaucoma
Targeting Oxidative Stress for Treatment of Glaucoma and Optic Neuritis.
Glioblastoma
A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
Glioblastoma
Analysis of PIK3CA and B-RAF gene mutations in human astrocytomas: association with activation of ERK and AKT.
Glioblastoma
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Glioblastoma
Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase- and B-Raf Proto-Oncogene-Wildtype Epithelioid Glioblastoma.
Glioblastoma
Mutation analysis of B-RAF gene in human gliomas.
Glioblastoma
Mutations of the MAPK/TSC/mTOR pathway characterize periventricular glioblastoma with epithelioid SEGA-like morphology-morphological and therapeutic implications.
Glioblastoma
RAF expression in human astrocytic tumors.
Glioblastoma
Regulation of the uPA gene in various grades of human glioma cells.
Glioblastoma
Regulation of the urokinase-type plasminogen activator receptor gene in different grades of human glioma cell lines.
Glioma
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Glioma
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
Glioma
Combined elevation of TRIB2 and MAP3K1 indicates poor prognosis and chemoresistance to temozolomide in glioblastoma.
Glioma
LRRC4 inhibits glioblastoma cell proliferation, migration, and angiogenesis by downregulating pleiotropic cytokine expression and responses.
Glioma
Mutation analysis of B-RAF gene in human gliomas.
Glioma
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Glioma
Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Glioma
Preclinical Pharmacological Evaluation of a Novel Multiple Kinase Inhibitor, ON123300, in Brain Tumor Models.
Glioma
RAF expression in human astrocytic tumors.
Glioma
To BRAF or not to BRAF: is that even a question anymore?
Gliosarcoma
Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
Glomerulonephritis
Inactivation of MAP3K7 in FOXD1-expressing cells results in loss of mesangial PDGFR? and juvenile kidney scarring.
Glomerulonephritis
Proto-oncogene expression in human glomerular diseases.
Glomerulonephritis
[Proto-oncogene, proliferating cell nuclear antigen, perforin and growth factor gene expression in peripheral blood mononuclear cells from patients with IgA nephropathy]
Glomerulonephritis, IGA
Proto-oncogene expression in peripheral blood mononuclear cells in IgA nephropathy.
Glomerulonephritis, IGA
[Proto-oncogene, proliferating cell nuclear antigen, perforin and growth factor gene expression in peripheral blood mononuclear cells from patients with IgA nephropathy]
glutamate-5-semialdehyde dehydrogenase deficiency
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Gonadal Dysgenesis
A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development.
Gonadal Dysgenesis
Human sex-determination and disorders of sex-development (DSD).
Gonadal Dysgenesis
MAP3K1-related gonadal dysgenesis: Six new cases and review of the literature.
Gonadal Dysgenesis
Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination.
Gonadal Dysgenesis
Mutations in MAP3K1 that cause 46,XY disorders of sex development disrupt distinct structural domains in the protein.
Gonadal Dysgenesis
Rapidly screening variants of uncertain significance in the MAP3K1 gene for phenotypic effects.
Hearing Loss
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Hearing Loss
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Hearing Loss
MEKK4 Signaling Regulates Sensory Cell Development and Function in the Mouse Inner Ear.
Hearing Loss
The goya mouse mutant reveals distinct newly identified roles for MAP3K1 in the development and survival of cochlear sensory hair cells.
Hearing Loss, Noise-Induced
Ablation of mixed lineage kinase 3 (Mlk3) does not inhibit ototoxicity induced by acoustic trauma or aminoglycoside exposure.
Hearing Loss, Sensorineural
The goya mouse mutant reveals distinct newly identified roles for MAP3K1 in the development and survival of cochlear sensory hair cells.
Heart Defects, Congenital
The phenotypic spectrum of proximal 6q deletions based on a large cohort derived from social media and literature reports.
Heart Diseases
Development of an HTS-compatible assay for the discovery of ASK1 signalosome inhibitors using alphascreen technology.
Heart Diseases
MEKK1 is essential for cardiac hypertrophy and dysfunction induced by Gq.
Heart Diseases
Silencing MEKK3 attenuates cardiomyocyte injury caused by hypoxia/reoxygenation via the sonic hedgehog pathway.
Heart Failure
A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy.
Heart Failure
Apoptosis signal-regulating kinase 1 attenuates atrial natriuretic peptide secretion.
Heart Failure
Progression of heart failure was suppressed by inhibition of apoptosis signal-regulating kinase 1 via transcoronary gene transfer.
Heart Failure
The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy.
Heart Failure
Tissue distribution and functional expression of a cDNA encoding a novel mixed lineage kinase.
Heart Failure
Transforming growth factor ?-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling.
Heart Septal Defects
Insights into the molecular pathogenesis of cardiospondylocarpofacial syndrome: MAP3K7 c.737-7A > G variant alters the TGF?-mediated ?-SMA cytoskeleton assembly and autophagy.
Hemangioma, Cavernous, Central Nervous System
Laser-scanning velocimetry: a confocal microscopy method for quantitative measurement of cardiovascular performance in zebrafish embryos and larvae.
Hemangioma, Cavernous, Central Nervous System
Micro-CT Imaging Reveals Mekk3 Heterozygosity Prevents Cerebral Cavernous Malformations in Ccm2-Deficient Mice.
Hemangioma, Cavernous, Central Nervous System
Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.
Hemangioma, Cavernous, Central Nervous System
Structural Insights into the Molecular Recognition between Cerebral Cavernous Malformation 2 and Mitogen-Activated Protein Kinase Kinase Kinase 3.
Hemangioma, Cavernous, Central Nervous System
The Cerebral Cavernous Malformation Pathway Controls Cardiac Development via Regulation of Endocardial MEKK3 Signaling and KLF Expression.
Hemangioma, Cavernous, Central Nervous System
The cerebral cavernous malformation proteins CCM2L and CCM2 prevent the activation of the MAP kinase MEKK3.
Hepatitis
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Hepatitis B
Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2.
Hepatitis C
Hepatitis C Virus NS5A Inhibits Mixed Lineage Kinase 3 to Block Apoptosis.
Hepatitis, Autoimmune
The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.
Herpes Simplex
Herpes simplex virus type 1 ICP27 induces p38 mitogen-activated protein kinase signaling and apoptosis in HeLa cells.
Herpes Zoster
Characterization of Porcine Multipotent Stem/Stromal Cells Derived from Skin, Adipose, and Ovarian Tissues and Their Differentiation In Vitro into Putative Oocyte-Like Cells.
Herpes Zoster
Functional analysis of oocyte-expressed genes using transgenic models.
Herpes Zoster
Oocyte-specific gene signaling and its regulation of mammalian reproductive potential.
Herpes Zoster
Ovary-selective genes I: the generation and characterization of an ovary-selective complementary deoxyribonucleic acid library.
Histiocytic Sarcoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Histiocytosis
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Histiocytosis
Histiocytic neoplasms in the era of personalized genomic medicine.
Histiocytosis
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Histiocytosis
The diagnostic pathology of the nuclear envelope in human cancers.
Histiocytosis, Langerhans-Cell
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease.
Histiocytosis, Langerhans-Cell
MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis.
Histiocytosis, Langerhans-Cell
The diagnostic pathology of the nuclear envelope in human cancers.
Hodgkin Disease
Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines.
Hodgkin Disease
The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2.
Hodgkin Disease
[Genetic polymorphism and susceptibility to cancer]
Huntington Disease
Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Hydatidiform Mole
c-mos immunoreactivity aids in the diagnosis of gestational trophoblastic lesions.
Hydatidiform Mole
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole.
Hyperalgesia
The role of P2X7R/ERK signaling in dorsal root ganglia satellite glial cells in the development of chronic postsurgical pain induced by skin/muscle incision and retraction (SMIR).
Hyperglycemia
Apoptosis Signal-Regulating Kinase 1 Mediates Cellular Senescence Induced by High Glucose in Endothelial Cells.
Hyperglycemia
Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.
Hyperglycemia
Maternal Hyperglycemia Activates an ASK1-FoxO3a-Caspase 8 Pathway That Leads to Embryonic Neural Tube Defects.
Hyperinsulinism
Protein Kinase Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Promotes Obesity-induced Hyperinsulinemia.
Hypersensitivity
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
Hypersensitivity
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Hypertension, Pulmonary
Apoptosis Signal-regulating Kinase 1 Inhibition in Pulmonary Hypertension: Too Much to ASK?
Hypertension, Pulmonary
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Hypospadias
Molecular diagnostics of disorders of sexual development: an Indian survey and systems biology perspective.
Infections
Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells.
Infections
An expanded subfamily of G-protein-coupled receptor genes in Fusarium graminearum required for wheat infection.
Infections
Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells.
Infections
B-Raf/Rap1 signaling, but not c-Raf-1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection.
Infections
Ce-Duox1/BLI-3 generated reactive oxygen species trigger protective SKN-1 activity via p38 MAPK signaling during infection in C. elegans.
Infections
Cell Signaling of Caenorhabditis elegans in Response to Enterotoxigenic Escherichia coli Infection and Lactobacillus zeae Protection.
Infections
Comparative transcriptional analysis of human macrophages exposed to animal and human isolates of Mycobacterium avium subspecies paratuberculosis with diverse genotypes.
Infections
Disruption of tight junctions and induction of proinflammatory cytokine responses in colonic epithelial cells by Campylobacter jejuni.
Infections
Down-regulation apoptosis signal-regulating kinase 1 gene reduced the Litopenaeus vannamei hemocyte apoptosis in WSSV infection.
Infections
Early-life long-term exposure to ZnO nanoparticles suppresses innate immunity regulated by SKN-1/Nrf and the p38 MAPK signaling pathway in Caenorhabditis elegans.
Infections
EspL is a bacterial cysteine protease effector that cleaves RHIM proteins to block necroptosis and inflammation.
Infections
Genome-wide identification of MAPKKK genes and their responses to phytoplasma infection in Chinese jujube (Ziziphus jujuba Mill.).
Infections
gga-miR-21 modulates Mycoplasma gallisepticum (HS strain)-Induced inflammation via targeting MAP3K1 and activating MAPKs and NF-?B pathways.
Infections
GhMAP3K65, a Cotton Raf-Like MAP3K Gene, Enhances Susceptibility to Pathogen Infection and Heat Stress by Negatively Modulating Growth and Development in Transgenic Nicotiana benthamiana.
Infections
H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses.
Infections
Identification and characterization of c-raf from orange-spotted grouper (Epinephelus coioides).
Infections
Identification of novel therapeutic targets for HIV infection through functional genomic cDNA screening.
Infections
Influenza Virus Infection Induces ZBP1 Expression and Necroptosis in Mouse Lungs.
Infections
Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells.
Infections
Interferon gamma induces cellular protein alteration and increases replication of porcine circovirus type 2 in PK-15 cells.
Infections
Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection.
Infections
Listeria monocytogenes infection of HeLa cells results in listeriolysin O-mediated transient activation of the Raf-MEK-MAP kinase pathway.
Infections
Macrophages inhibit Salmonella typhimurium replication through MEK/ERK kinase and phagocyte NADPH oxidase activities.
Infections
MEKK1 is required for MPK4 activation and regulates tissue-specific and temperature-dependent cell death in Arabidopsis.
Infections
MEKK3 and TAK1 synergize to activate IKK complex in Helicobacter pylori infection.
Infections
MLKL Requires the Inositol Phosphate Code to Execute Necroptosis.
Infections
Mouse cytomegalovirus M36 and M45 death suppressors cooperate to prevent inflammation resulting from antiviral programmed cell death pathways.
Infections
Mycobacteria induce TPL-2 mediated IL-10 in IL-4-generated alternatively activated macrophages.
Infections
Physiological roles of ASK family members in innate immunity and their involvement in pathogenesis of immune diseases.
Infections
Raf/MEK/ERK signalling triggers reactivation of Kaposi's sarcoma-associated herpesvirus latency.
Infections
Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells.
Infections
Roquin-2 promotes ubiquitin-mediated degradation of ASK1 to regulate stress responses.
Infections
Suppression of extracellular signal-regulated kinase activity in herpes simplex virus 1-infected cells by the Us3 protein kinase.
Infections
Sustained activation of Akt and Erk1/2 is required for Coxiella burnetii antiapoptotic activity.
Infections
The Ectopic Expression of CaRop1 Modulates the Response of Tobacco Plants to Ralstonia solanacearum and Aphids.
Infections
The MAPKKK Mekk1 regulates the expression of Turandot stress genes in response to septic injury in Drosophila.
Infections
TPL-2 Regulates Macrophage Lipid Metabolism and M2 Differentiation to Control TH2-Mediated Immunopathology.
Infections
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
Infections
Transcriptome-based analysis of mitogen-activated protein kinase cascades in the rice response to Xanthomonas oryzae infection.
Infections
Transcriptomic Response to Nitric Oxide Treatment in Larix olgensis Henry.
Infections
Varicella-zoster virus influences the activities of components and targets of the ERK signalling pathway.
Infections
Viral-induced systemic necrosis in plants involves both programmed cell death and the inhibition of viral multiplication, which are regulated by independent pathways.
Infertility
A dominant truncation allele identifies a gene, STE20, that encodes a putative protein kinase necessary for mating in Saccharomyces cerevisiae.
Infertility
A gene-specific requirement of RNA polymerase II CTD phosphorylation for sexual differentiation in S. pombe.
Infertility
A zinc-finger protein, Rst2p, regulates transcription of the fission yeast ste11(+) gene, which encodes a pivotal transcription factor for sexual development.
Infertility
Interactions among the subunits of the G protein involved in Saccharomyces cerevisiae mating.
Infertility
Role of STE genes in the mating factor signaling pathway mediated by GPA1 in Saccharomyces cerevisiae.
Infertility
The RNA binding protein Csx1 promotes sexual differentiation in Schizosaccharomyces pombe.
Inflammatory Bowel Diseases
Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.
Inflammatory Bowel Diseases
Regulation and function of TPL-2, an I?B kinase-regulated MAP kinase kinase kinase.
Influenza, Human
Differential Responses to Rhinovirus and Influenza-associated Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Influenza, Human
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.
Influenza, Human
Lung-specific expression of active Raf kinase results in increased mortality of influenza A virus-infected mice.
Influenza, Human
Mixed Lineage Kinase 3 deficiency delays viral clearance in the lung and is associated with diminished influenza-induced cytopathic effect in infected cells.
Insulin Resistance
Association of common genetic variants in the MAP4K4 locus with prediabetic traits in humans.
Insulin Resistance
Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.
Insulin Resistance
Protein Kinase Mitogen-activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Promotes Obesity-induced Hyperinsulinemia.
Insulin Resistance
Resistin promotes cardiac hypertrophy via AMPK/mTOR and JNK/IRS1 pathways.
Insulin Resistance
The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.
Insulinoma
Pyruvate kinase M1 interacts with A-Raf and inhibits endoplasmic reticulum stress-induced apoptosis by activating MEK1/ERK pathway in mouse insulinoma cells.
Insulinoma
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Insulinoma
Stimulation of B-Raf increases c-Jun and c-Fos expression and upregulates AP-1-regulated gene transcription in insulinoma cells.
Intestinal Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Keratoacanthoma
Regression of B-RAF inhibitor associated keratoacanthomas by acitretin - how do retinoids act on the RAF/MEK/ERK-signaling pathway?
Kidney Diseases
ASK1: a new therapeutic target for kidney disease.
Kidney Diseases
Effects of Selonsertib in Patients with Diabetic Kidney Disease.
Kidney Diseases
MAP3K kinases and kidney injury.
Kidney Diseases
TGF-{beta}1 activated kinase-1 (TAK1) regulates inflammation and fibrosis in the obstructed kidney.
Kidney Neoplasms
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Kidney Neoplasms
Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus.
Kidney Neoplasms
The Expression and Role of MEKK3 in Renal Clear Cell Carcinoma.
LEOPARD Syndrome
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
Leukemia
A generalized method of subcloning DNA fragments by restriction site reconstruction: application to sequencing the amino-terminal coding region of the transforming gene of Gazdar murine sarcoma virus.
Leukemia
A single point mutation responsible for c-mos polymorphism in cancer patients.
Leukemia
Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.
Leukemia
B-Raf Inhibition in the Clinic: Present and Future.
Leukemia
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Leukemia
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Leukemia
Cot kinase regulation of IL-2 production in Jurkat T cells.
Leukemia
Essential role of the 58-kDa microspherule protein in the modulation of Daxx-dependent transcriptional repression as revealed by nucleolar sequestration.
Leukemia
Expression and activation of B-Raf kinase isoforms in human and murine leukemia cell lines.
Leukemia
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Leukemia
GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Integration of transfected LTR sequences into the c-raf proto-oncogene: activation by promoter insertion.
Leukemia
Localization of the human c-mos gene by in situ hybridization in two cases of acute nonlymphocytic leukemia type M2.
Leukemia
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-?B.
Leukemia
Molecular cloning and characterization of a leukemia-inducing myeloproliferative sarcoma virus and two of its temperature-sensitive mutants.
Leukemia
Necroptosis Interfaces with MOMP and the MPTP in Mediating Cell Death.
Leukemia
Proto-oncogene expression in human normal bone marrow.
Leukemia
Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9.
Leukemia
Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells.
Leukemia
Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues.
Leukemia
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Leukemia
Sorafenib inhibits therapeutic induction of necroptosis in acute leukemia cells.
Leukemia
Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1).
Leukemia
The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells.
Leukemia
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Leukemia
The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells.
Leukemia
The role of the c-mos gene in the 8;21 translocation in human acute myeloblastic leukemia.
Leukemia
Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.
Leukemia
Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.
Leukemia
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Leukemia
[Expression and kinase activity of B-Raf and Raf-1 in leukemia cell lines]
Leukemia, Erythroblastic, Acute
Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Leukemia, Hairy Cell
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Leukemia, Hairy Cell
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
Leukemia, Myeloid
Identification in several human myeloid leukemias or cell lines of a DNA rearrangement next to the c-mos 3'-end.
Leukemia, Myeloid
RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines.
Leukemia, Myeloid
Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Leukemia, Myeloid
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Leukemia, Myeloid, Acute
Hu-ets-2 is translocated to chromosome 8 in the t(8;21) in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Isolation and analysis of the 21q+ chromosome in the acute myelogenous leukemia 8;21 translocation: evidence that c-mos is not translocated.
Leukemia, Myeloid, Acute
Localization of human c-mos to chromosome band 8q11 in leukemic cells with the t(8;21) (q22;q22).
Leukemia, Myeloid, Acute
Localization of the human c-mos gene by in situ hybridization in two cases of acute nonlymphocytic leukemia type M2.
Leukemia, Myeloid, Acute
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Leukemia, Myeloid, Acute
Prognostic Value of mRNA Expression of MAP4K Family in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
The role of the c-mos gene in the 8;21 translocation in human acute myeloblastic leukemia.
Leukemia, Myeloid, Acute
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.
Leukemia, T-Cell
Activation of the heterodimeric IkappaB kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions.
Leukoplakia, Oral
Peroxiredoxin 1 suppresses apoptosis via regulation of the apoptosis signal-regulating kinase 1 signaling pathway in human oral leukoplakia.
Liposarcoma
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Liver Diseases
Decrease in fat de novo synthesis and chemokine ligand expression in non-alcoholic fatty liver disease caused by inhibition of mixed lineage kinase domain-like pseudokinase.
Liver Diseases
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade.
Liver Neoplasms
B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Liver Neoplasms
Cross-talk between aryl hydrocarbon receptor and mitogen-activated protein kinase signaling pathway in liver cancer through c-raf transcriptional regulation.
Liver Neoplasms
Expression of the c-raf protooncogene, gamma-glutamyltranspeptidase, and gap junction protein in rat liver neoplasms.
Liver Neoplasms
miR24-2 accelerates progression of liver cancer cells by activating Pim1 through tri-methylation of Histone H3 on the ninth lysine.
Liver Neoplasms
The MAP3K TAK1: a chock block to liver cancer formation.
Lung Injury
Deletion of Apoptosis Signal Regulating Kinase-1 Prevents Ventilator-induced Lung Injury In Mice.
Lung Neoplasms
A cross-platform comparison of affymetrix and Agilent microarrays reveals discordant miRNA expression in lung tumors of c-Raf transgenic mice.
Lung Neoplasms
Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.
Lung Neoplasms
Apoptosis Signal-Regulating Kinase 1 (ASK1) Activation is Involved in Silver Nanoparticles Induced Apoptosis of A549 Lung Cancer Cell Line.
Lung Neoplasms
B-RAF mutation in non-small cell lung cancer: the sleeping beauty is waking up.
Lung Neoplasms
Biomarkers in non-small cell lung cancer prevention.
Lung Neoplasms
Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide.
Lung Neoplasms
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Lung Neoplasms
c-mos immunoreactivity is an indicator of good prognosis in lung cancer.
Lung Neoplasms
C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
Lung Neoplasms
C-Raf is required for the initiation of lung cancer by K-Ras.
Lung Neoplasms
Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
Lung Neoplasms
Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology.
Lung Neoplasms
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Lung Neoplasms
Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF).
Lung Neoplasms
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
Lung Neoplasms
Downregulation of PKC?/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.
Lung Neoplasms
Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors.
Lung Neoplasms
FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2.
Lung Neoplasms
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Lung Neoplasms
Heat shock protein 90 inhibition in lung cancer.
Lung Neoplasms
Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Lung Neoplasms
MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.
Lung Neoplasms
miR-145-5p inhibits epithelial-mesenchymal transition via the JNK signaling pathway by targeting MAP3K1 in non-small cell lung cancer cells.
Lung Neoplasms
miRNAs deregulation in serum of mice is associated with lung cancer related pathway deregulation induced by PM2.5.
Lung Neoplasms
Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells.
Lung Neoplasms
Multiple primary malignant neoplasms: A case report and literature review.
Lung Neoplasms
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Lung Neoplasms
Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth.
Lung Neoplasms
RAF expression in human astrocytic tumors.
Lung Neoplasms
Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation.
Lung Neoplasms
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Lung Neoplasms
RUVBL1, a novel C-RAF-binding protein, activates the RAF/MEK/ERK pathway to promote lung cancer tumorigenesis.
Lung Neoplasms
Safety and proof-of-concept efficacy of inhaled drug loaded nano- and immunonanoparticles in a c-Raf transgenic lung cancer model.
Lung Neoplasms
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Lung Neoplasms
Targeted Lung Cancer Treatments and Eye Metastasis.
Lung Neoplasms
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Lung Neoplasms
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
Lung Neoplasms
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Lung Neoplasms
[Effect of celastrol in inhibiting metastasis of lung cancer cells by influencing Akt signaling pathway and expressing integrins].
Lupus Erythematosus, Systemic
AhR-ROR-?t complex is a therapeutic target for MAP4K3/GLKhighIL-17Ahigh subpopulation of systemic lupus erythematosus.
Lupus Nephritis
Proto-oncogene expression in human glomerular diseases.
Lymphatic Metastasis
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Lymphoma
Activation of MEK-1 and SEK-1 by Tpl-2 proto-oncoprotein, a novel MAP kinase kinase kinase.
Lymphoma
Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation: A case report and literature review.
Lymphoma
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Lymphoma
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: A highly active combination against human mantle cell lymphoma (MCL) cells.
Lymphoma
Computational algorithms for in silico profiling of activating mutations in cancer.
Lymphoma
Continuous overexpression of thioredoxin 1 enhances cancer development and does not extend maximum lifespan in male C57BL/6 mice.
Lymphoma
Cot kinase regulation of IL-2 production in Jurkat T cells.
Lymphoma
EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer.
Lymphoma
Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.
Lymphoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Lymphoma
Kinase group protooncogenes in non-hodgkins-lymphomas and nonmalignant lymphoid-tissues - analysis of their expression by insitu hybridization assays.
Lymphoma
Molecular alterations in non-small cell lung carcinomas of the young.
Lymphoma
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
Lymphoma
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Lymphoma
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.
Lymphoma
Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration.
Lymphoma
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Lymphoma
Targeted Lung Cancer Treatments and Eye Metastasis.
Lymphoma
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Lymphoma
Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation.
Lymphoma
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Lymphoma
TRAIL activates JNK and NF-?B through RIP1-dependent and -independent pathways.
Lymphoma
Understanding and targeting resistance mechanisms in NSCLC.
Lymphoma
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Lymphoma, B-Cell
Activation of the apoptosis signal-regulating kinase 1/c-Jun N-terminal kinase pathway is involved in the casticin-induced apoptosis of colon cancer cells.
Lymphoma, B-Cell
Docking-based inverse virtual screening strategy for identification of novel protein targets for triclosan.
Lymphoma, B-Cell
Effects of prostaglandin F2? (PGF2?) on cell-death pathways in the bovine corpus luteum (CL).
Lymphoma, B-Cell
Identification of collaborative activities with oxidative phosphorylation in bipolar disorder.
Lymphoma, B-Cell
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.
Lymphoma, B-Cell
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia.
Lymphoma, B-Cell
TPL-2 MEK kinase is not targeted by mutation in diffuse large B cell lymphoma and myeloid leukemia.
Lymphoma, Non-Hodgkin
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
Lymphoma, Non-Hodgkin
Trisomy 8 in human hematologic neoplasia and the c-myc and c-mos oncogenes.
Lymphoma, T-Cell
Genomic organization and expression of Tpl-2 in normal cells and Moloney murine leukemia virus-induced rat T-cell lymphomas: activation by provirus insertion.
Lymphoma, T-Cell
Structure of a Moloney murine leukemia virus-virus-like 30 recombinant: implications for transduction of the c-Ha-ras proto-oncogene.
Lymphoma, T-Cell
Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation.
Lymphoma, T-Cell
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
Lymphoma, T-Cell, Cutaneous
The Expression of IL-21 Is Promoted by MEKK4 in Malignant T Cells and Associated with Increased Progression Risk in Cutaneous T-Cell Lymphoma.
Lymphoproliferative Disorders
Proto-oncogene allelic variations in human squamous cell carcinomas of the larynx.
Measles
The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity.
Medulloblastoma
MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function.
Medulloblastoma
Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation.
Megalencephaly
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Melanoma
1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
Melanoma
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Melanoma
5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
Melanoma
A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations.
Melanoma
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma.
Melanoma
A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells.
Melanoma
A new B-Raf inhibitor combo for advanced melanoma.
Melanoma
A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker.
Melanoma
A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.
Melanoma
A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth.
Melanoma
A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors.
Melanoma
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Melanoma
A prognostic signature of G 2 checkpoint function in melanoma cell lines.
Melanoma
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Melanoma
A(nother) RAF mutation in LCH.
Melanoma
Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.
Melanoma
Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Melanoma
Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System.
Melanoma
Activating the Wnt/?-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Melanoma
Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase).
Melanoma
Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells.
Melanoma
Active Notch1 confers a transformed phenotype to primary human melanocytes.
Melanoma
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.
Melanoma
Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Melanoma
Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction.
Melanoma
Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells.
Melanoma
Advanced Melanoma: A Progressive Review of V600E-B-RAF Kinase And Drugs Inhibiting It.
Melanoma
Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Melanoma
Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
Melanoma
alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.
Melanoma
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Melanoma
Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.
Melanoma
Anti-inflammatory effects of dabrafenib in vitro and in vivo.
Melanoma
Anti-inflammatory effects of dabrafenib on polyphosphate-mediated vascular disruption.
Melanoma
Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses.
Melanoma
Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E.
Melanoma
Anticancer potential of benzothiazolic derivative (E)-2-((2-(benzo[d]thiazol-2-yl)hydrazono)methyl)-4-nitrophenol against melanoma cells.
Melanoma
Antiseptic effects of dabrafenib on TGFBIp-induced septic responses.
Melanoma
Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
Melanoma
Are all melanomas the same?: spitzoid melanoma is a distinct subtype of melanoma.
Melanoma
Aryl Hydrocarbon Receptor Modulates Carcinogenesis and Maintenance of Skin Cancers.
Melanoma
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.
Melanoma
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
Melanoma
Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf.
Melanoma
B-Raf and C-Raf are required for melanocyte stem cell self-maintenance.
Melanoma
B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Melanoma
B-RAF and melanocytic neoplasia.
Melanoma
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Melanoma
B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis.
Melanoma
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms.
Melanoma
B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger.
Melanoma
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Melanoma
B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.
Melanoma
B-Raf Inhibition in the Clinic: Present and Future.
Melanoma
B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Melanoma
B-RAF inhibitors: an evolving role in the therapy of malignant melanoma.
Melanoma
B-RAF is a therapeutic target in melanoma.
Melanoma
B-Raf kinase inhibitors for cancer treatment.
Melanoma
B-Raf mutation: a key player in molecular biology of cancer.
Melanoma
B-RAF mutations are a rare event in pituitary adenomas.
Melanoma
B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas.
Melanoma
B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization.
Melanoma
B-Raf specific antibody responses in melanoma patients.
Melanoma
B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Melanoma
B-RAF, naevi and melanoma: a complex relationship.
Melanoma
B-RAF: A contributor to the melanoma phenotype.
Melanoma
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Melanoma
Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.
Melanoma
BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?
Melanoma
BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
Melanoma
c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis.
Melanoma
c-Myc modulation: a key role in melanoma drug response.
Melanoma
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Melanoma
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Melanoma
CD133? melanoma subpopulation acquired resistance to caffeic acid phenethyl ester-induced apoptosis is attributed to the elevated expression of ABCB5: significance for melanoma treatment.
Melanoma
CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.
Melanoma
Characterization of vemurafenib phototoxicity in a mouse model.
Melanoma
Chemoprevention of melanoma.
Melanoma
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Melanoma
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Melanoma
Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Melanoma
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Melanoma
Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas.
Melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Melanoma
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts.
Melanoma
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Melanoma
Computational algorithms for in silico profiling of activating mutations in cancer.
Melanoma
Computational study on the unbinding pathways of B-RAF inhibitors and its implication for the difference of residence time: insight from random acceleration and steered molecular dynamics simulations.
Melanoma
Concomitant Inhibition of PI3K? and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K?-Selective Inhibitor.
Melanoma
Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.
Melanoma
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Melanoma
Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Melanoma
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Melanoma
Critical role of miR-10b in B-RafV600E dependent anchorage independent growth and invasion of melanoma cells.
Melanoma
Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma.
Melanoma
Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Melanoma
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Melanoma
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression.
Melanoma
Cytotoxicity of amide-linked local anesthetics on melanoma cells via inhibition of Ras and RhoA signaling independent of sodium channel blockade.
Melanoma
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Melanoma
Dabrafenib in the treatment of advanced melanoma.
Melanoma
Dabrafenib, an inhibitor of RIP3 kinase-dependent necroptosis, reduces ischemic brain injury.
Melanoma
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.
Melanoma
Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors.
Melanoma
Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Melanoma
Detection of B-RAF and N-RAS mutations in human melanoma.
Melanoma
Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Melanoma
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Melanoma
Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.
Melanoma
Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico.
Melanoma
Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.
Melanoma
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Melanoma
Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Melanoma
Discovery and Optimization of a Novel Series of Potent Mutant B-Raf(V600E) Selective Kinase Inhibitors.
Melanoma
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
Melanoma
Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.
Melanoma
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Melanoma
Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation.
Melanoma
Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment.
Melanoma
Energetics and structural characterization of the "DFG-flip" conformational transition of B-RAF kinase: a SITS molecular dynamics study.
Melanoma
ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.
Melanoma
Evaluation of (fli:GFP) Casper Zebrafish Embryos as a Model for Human Conjunctival Melanoma.
Melanoma
Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.
Melanoma
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Melanoma
Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.
Melanoma
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells.
Melanoma
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.
Melanoma
Fisetin: a natural fist against melanoma?
Melanoma
FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells.
Melanoma
FOXD3 regulates migratory properties and Rnd3 expression in melanoma cells.
Melanoma
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Melanoma
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Melanoma
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma.
Melanoma
Genetic similarities between Spitz nevus and Spitzoid melanoma in children.
Melanoma
Genotype-Dependent Sensitivity Of Uveal Melanoma Cell Lines To Inhibition of B-Raf, MEK And Akt Kinases: Rationale For Personalized Therapy.
Melanoma
GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax.
Melanoma
Glutamatergic Pathway Targeting in Melanoma; Single Agent and Combinatorial Therapies.
Melanoma
Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Melanoma
Heme oxygenase 1 facilitates cell proliferation via the B-Raf-ERK signaling pathway in melanoma.
Melanoma
Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma.
Melanoma
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Melanoma
HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Melanoma
Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Melanoma
Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.
Melanoma
Identification of novel B-Raf(V600E) inhibitors employing FBDD strategy.
Melanoma
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Melanoma
Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
Melanoma
IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin.
Melanoma
IGFBP7 is not required for B-RAF-induced melanocyte senescence.
Melanoma
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Melanoma
Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
Melanoma
In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease.
Melanoma
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas.
Melanoma
Induction of apoptosis signal-regulating Kinase 1 by E2F-1 may not be essential for E2F-1-mediated apoptosis in melanoma cells.
Melanoma
Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation.
Melanoma
Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing.
Melanoma
Inhibition of mutated, activated BRAF in metastatic melanoma.
Melanoma
Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation.
Melanoma
Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
Melanoma
Intermittent B-Raf inhibitor therapy is a feasible option -report of a patient with metastatic melanoma.
Melanoma
Involvement of human beta-defensin-2 in regulation of malignant potential of cultured human melanoma cells.
Melanoma
Is B-Raf a good therapeutic target for melanoma and other malignancies?
Melanoma
Is Mcl-1L the new anti-apoptotic effector of B-RAFV(600E) in melanoma?
Melanoma
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
Melanoma
Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.
Melanoma
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.
Melanoma
Latest approved therapies for metastatic melanoma: what comes next?
Melanoma
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Melanoma
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Melanoma
Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time qPCR.
Melanoma
Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma.
Melanoma
Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Melanoma
Malignant melanoma--a genetic overview.
Melanoma
Mcl-1 is required for melanoma cell resistance to anoikis.
Melanoma
Mechanisms of apoptosis induced by anticancer compounds in melanoma cells.
Melanoma
Mechanisms of regulating the Raf kinase family.
Melanoma
Mechanisms of Resistance to RAF Inhibitors in Melanoma.
Melanoma
MEK and PI3K inhibition in solid tumors: rationale and evidence to date.
Melanoma
MEK targeting in N-RAS mutated metastatic melanoma.
Melanoma
MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.
Melanoma
MEK1 mutations confer resistance to MEK and B-RAF inhibition.
Melanoma
MELANOMA ADJUVANT TREATMENT: current insight and clinical features.
Melanoma
Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Melanoma
Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.
Melanoma
Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy.
Melanoma
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.
Melanoma
Metabolic imaging using hyperpolarized 13 C-pyruvate to assess sensitivity to the B-Raf inhibitor vemurafenib in melanoma cells and xenografts.
Melanoma
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
Melanoma
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Melanoma
MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.
Melanoma
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
Melanoma
MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma.
Melanoma
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Melanoma
Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma.
Melanoma
Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
Melanoma
Modulation of plasma metabolite biomarkers of MAPK pathway with the MEK inhibitor RO4987655: pharmacodynamic and predictive potential in metastatic melanoma.
Melanoma
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Melanoma
Monitoring oncogenic B-RAF-induced senescence in melanocytes.
Melanoma
Mouse model for pre-clinical study of human cancer immunotherapy.
Melanoma
Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
Melanoma
Mutant B-RAF mediates resistance to anoikis via Bad and Bim.
Melanoma
Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma.
Melanoma
Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
Melanoma
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Melanoma
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Melanoma
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Melanoma
Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients.
Melanoma
Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors.
Melanoma
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.
Melanoma
Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma.
Melanoma
New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.
Melanoma
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Melanoma
No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
Melanoma
Nodular Regenerative Hyperplasia Associated with Immune Checkpoint Blockade.
Melanoma
Non-melanoma skin cancer in mouse and man.
Melanoma
Novel biomarkers in malignant melanoma.
Melanoma
Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Melanoma
Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.
Melanoma
Novel mechanisms of resistance to vemurafenib in melanoma - V600E B-Raf reversion and switching VEGF-A splice isoform expression.
Melanoma
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
Melanoma
Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions.
Melanoma
Oncogenic B-RAF signalling in melanoma impairs the therapeutic advantage of autophagy inhibition.
Melanoma
Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.
Melanoma
Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion.
Melanoma
Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim.
Melanoma
Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Melanoma
Overcoming Drug Resistance to BRAF Inhibitor.
Melanoma
p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
Melanoma
Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Melanoma
Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors.
Melanoma
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Melanoma
Phenotype characterization of human melanoma cells resistant to dabrafenib.
Melanoma
Phosphoethanolamine induces caspase-independent cell death by reducing the expression of C-RAF and inhibits tumor growth in human melanoma model.
Melanoma
Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
Melanoma
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells.
Melanoma
PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.
Melanoma
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Melanoma
Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties.
Melanoma
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Melanoma
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Melanoma
Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature.
Melanoma
Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study.
Melanoma
Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
Melanoma
Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation.
Melanoma
Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas.
Melanoma
Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
Melanoma
Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability.
Melanoma
Raf kinases: Oncogenesis and drug discovery.
Melanoma
RAF protein-serine/threonine kinases: structure and regulation.
Melanoma
Raf proteins and cancer: B-Raf is identified as a mutational target.
Melanoma
Ras-mutant Cancer Cells Display B-Raf Binding to Ras That Activates Extracellular Signal-regulated Kinase and Is Inhibited by Protein Kinase A Phosphorylation.
Melanoma
RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Melanoma
Rb-Raf-1 interaction disruptor RRD-251 induces apoptosis in metastatic melanoma cells and synergizes with dacarbazine.
Melanoma
Rb/E2F: a two-edged sword in the melanocytic system.
Melanoma
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Melanoma
Recent Advances in the Research and Development of B-Raf Inhibitors.
Melanoma
Recent advances of MEK inhibitors and their clinical progress.
Melanoma
Regulation of Raf through phosphorylation and N terminus-C terminus interaction.
Melanoma
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Melanoma
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Melanoma
RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
Melanoma
RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.
Melanoma
Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions.
Melanoma
Role of Melanoma Inhibitor of Apoptosis (ML-IAP) Protein, a Member of the Baculoviral IAP Repeat (BIR) Domain Family, in the Regulation of C-RAF Kinase and Cell Migration.
Melanoma
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Melanoma
Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Melanoma
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.
Melanoma
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Melanoma
Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside.
Melanoma
Similar nucleotide excision repair capacity in melanocytes and melanoma cells.
Melanoma
Skp2 regulates G2/M progression in a p53-dependent manner.
Melanoma
So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.
Melanoma
Somatic p16(INK4a) loss accelerates melanomagenesis.
Melanoma
Sorafenib induces synergistic effect on inhibition of vemurafenib resistant melanoma growth.
Melanoma
Specialty pharmacy services for patients receiving oral medications for solid tumors.
Melanoma
Structural Optimization and Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin-Like Functionalities as B-Raf Inhibitors.
Melanoma
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Melanoma
Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision.
Melanoma
Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone.
Melanoma
Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death.
Melanoma
Suppressive effects of dabrafenib on endothelial protein C receptor shedding.
Melanoma
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Melanoma
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin.
Melanoma
Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues.
Melanoma
TAK1 suppresses RIPK1-dependent cell death and is associated with disease progression in melanoma.
Melanoma
Targeted therapies in brain metastases.
Melanoma
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
Melanoma
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Melanoma
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Melanoma
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Melanoma
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.
Melanoma
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Melanoma
Targeting oxidative phosphorylation: why, when, and how.
Melanoma
Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail.
Melanoma
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Melanoma
Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Melanoma
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
Melanoma
Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.
Melanoma
Targets of Raf in tumorigenesis.
Melanoma
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Melanoma
The diagnostic pathology of the nuclear envelope in human cancers.
Melanoma
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell death.
Melanoma
The effect of a widespread cancer-causing mutation on the inactive to active dynamics of the B-Raf kinase.
Melanoma
The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
Melanoma
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Melanoma
The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes.
Melanoma
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Melanoma
The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Melanoma
The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Melanoma
The role of B-RAF in melanoma.
Melanoma
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-?B/Snail/RKIP/PTEN Circuit.
Melanoma
The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment.
Melanoma
The use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.
Melanoma
Towards new therapeutic approaches for malignant melanoma.
Melanoma
Trametinib for the treatment of melanoma.
Melanoma
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Melanoma
Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.
Melanoma
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
Melanoma
Two distinct steps of Bak regulation during apoptotic stress signaling: different roles of MEKK1 and JNK1.
Melanoma
U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo.
Melanoma
Understanding signaling cascades in melanoma.
Melanoma
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Melanoma
Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.
Melanoma
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy.
Melanoma
V599EB-RAF is an oncogene in melanocytes.
Melanoma
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Melanoma
Vemurafenib-Associated Keratoses With Genetic Heterogeneity of RAS.
Melanoma
Vemurafenib: the road to personalized medicine in melanoma.
Melanoma
Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.
Melanoma
What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.
Melanoma
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Melanoma
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi.
Melanoma
[Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Melanoma
[Dabrafenib: the new inhibitor of hyperactive B-RAF kinase].
Melanoma
[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
Melanoma
[Inactivation of Receptor Tyrosine Kinases Overcomes Resistance to Targeted B-RAF Inhibitors in Melanoma Cell Lines].
Melanoma
[MAP-Kinase pathway abnormalities in melanoma: B-RAF is not the sole cause].
Melanoma
[Treatment of patients with brain metastases from a melanoma].
Melanoma
[Whats new in dermato-oncology?].
Melanoma, Experimental
Mouse model for pre-clinical study of human cancer immunotherapy.
Menkes Kinky Hair Syndrome
Unique presentation of cutis laxa with Leigh-like syndrome due to ECHS1 deficiency.
Metabolic Syndrome
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency accelerates hyperlipidemia-induced atheromatous plaques via suppression of macrophage apoptosis.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency attenuates vascular injury-induced neointimal hyperplasia by suppressing apoptosis in smooth muscle cells.
mitogen-activated protein kinase kinase kinase deficiency
Apoptosis signal-regulating kinase 1 deficiency eliminates cardiovascular injuries induced by high-salt diet.
mitogen-activated protein kinase kinase kinase deficiency
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
mitogen-activated protein kinase kinase kinase deficiency
B-Raf is required for positive selection and survival of DP cells, but not for negative selection of SP cells.
mitogen-activated protein kinase kinase kinase deficiency
C-Raf deficiency leads to hearing loss and increased noise susceptibility.
mitogen-activated protein kinase kinase kinase deficiency
Data on tumor progression of c-mos deficiency in murine models of Kras
G12D
lung and Apc
Min
colorectal cancer.
mitogen-activated protein kinase kinase kinase deficiency
Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?
mitogen-activated protein kinase kinase kinase deficiency
Impairment of cardiomyogenesis in embryonic stem cells lacking scaffold protein JSAP1.
mitogen-activated protein kinase kinase kinase deficiency
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
mitogen-activated protein kinase kinase kinase deficiency
MEKK1 regulates calpain-dependent proteolysis of focal adhesion proteins for rear-end detachment of migrating fibroblasts.
mitogen-activated protein kinase kinase kinase deficiency
MEKK3 Regulates IFN-{gamma} Production in T Cells through the Rac1/2-Dependent MAPK Cascades.
mitogen-activated protein kinase kinase kinase deficiency
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice.
mitogen-activated protein kinase kinase kinase deficiency
Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes.
mitogen-activated protein kinase kinase kinase deficiency
Silencing MEKK3 attenuates cardiomyocyte injury caused by hypoxia/reoxygenation via the sonic hedgehog pathway.
mitogen-activated protein kinase kinase kinase deficiency
Structure and vascular function of MEKK3-cerebral cavernous malformations 2 complex.
mitogen-activated protein kinase kinase kinase deficiency
TPL-2 restricts Ccl24-dependent immunity to Heligmosomoides polygyrus.
mitogen-activated protein kinase kinase kinase deficiency
Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells.
Motor Neuron Disease
ZPK/DLK, a mitogen-activated protein kinase kinase kinase, is a critical mediator of programmed cell death of motoneurons.
Mouth Neoplasms
Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway.
Multiple Endocrine Neoplasia
Patterns of neoplasia in c-mos transgenic mice and their relevance to multiple endocrine neoplasia.
Multiple Endocrine Neoplasia
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Multiple Endocrine Neoplasia Type 2a
Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.
Multiple Myeloma
Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.
Multiple Myeloma
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Multiple Sclerosis
Regulation of Experimental Autoimmune Encephalomyelitis by TPL-2 Kinase.
Multiple Sclerosis
Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.
Muscular Atrophy
Gadd45a Protein Promotes Skeletal Muscle Atrophy by Forming a Complex with the Protein Kinase MEKK4.
Mycoses
The Arabidopsis MAPKKK ?-1 is required for full immunity against bacterial and fungal infection.
Myocardial Infarction
An Apoptosis Signal-regulating Kinase 1 Inhibitor Reduces Cardiomyocyte Apoptosis and Infarct Size in a Rat Ischemia-reperfusion Model.
Myocardial Infarction
Heat-shock protein 90 modulates cardiac ventricular hypertrophy via activation of MAPK pathway.
Myocardial Infarction
Platelet MEKK3 regulates arterial thrombosis and myocardial infarct expansion in mice.
Myocardial Infarction
Possible mechanisms behind cardiac troponin elevations.
Narcolepsy
Whole-Proteome Peptide Microarrays for Profiling Autoantibody Repertoires within Multiple Sclerosis and Narcolepsy.
Nasopharyngeal Carcinoma
The oncogenic protein kinase Tpl-2/Cot contributes to Epstein-Barr virus-encoded latent infection membrane protein 1-induced NF-kappaB signaling downstream of TRAF2.
Neoplasm Metastasis
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.
Neoplasm Metastasis
ASK1 facilitates tumor metastasis through phosphorylation of an ADP receptor P2Y12 in platelets.
Neoplasm Metastasis
Association of Mixed Lineage Kinase Domain-Like Protein Expression With Prognosis in Patients With Colon Cancer.
Neoplasm Metastasis
B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
Neoplasm Metastasis
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Neoplasm Metastasis
Chemotherapy-induced miR-141/MAP4K4 signaling suppresses progression of colorectal cancer.
Neoplasm Metastasis
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Neoplasm Metastasis
Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Neoplasm Metastasis
Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis.
Neoplasm Metastasis
Demethylation-induced overexpression of Shc3 drives c-Raf-independent activation of MEK/ERK in HCC.
Neoplasm Metastasis
Depleting MEKK1 expression inhibits the ability of invasion and migration of human pancreatic cancer cells.
Neoplasm Metastasis
Detection of B-RAF and N-RAS mutations in human melanoma.
Neoplasm Metastasis
Detection of mutations in the mitogen-activated protein kinase pathway in human melanoma.
Neoplasm Metastasis
Development and Validation of a High-Throughput Intrinsic ATPase Activity Assay for the Discovery of MEKK2 Inhibitors.
Neoplasm Metastasis
Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).
Neoplasm Metastasis
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
Neoplasm Metastasis
Expression of Raf kinase inhibitor protein is downregulated in response to Newcastle disease virus infection to promote viral replication.
Neoplasm Metastasis
Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells.
Neoplasm Metastasis
Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
Neoplasm Metastasis
Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer.
Neoplasm Metastasis
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.
Neoplasm Metastasis
Hematopoietic progenitor kinase 1, mitogen-activated protein/extracellular signal-related protein kinase kinase kinase 1, and phosphomitogen-activated protein kinase kinase 4 are overexpressed in extramammary Paget disease.
Neoplasm Metastasis
Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity.
Neoplasm Metastasis
Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Neoplasm Metastasis
Isolation and molecular characterization of circulating melanoma cells.
Neoplasm Metastasis
Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
Neoplasm Metastasis
MAP3K1-targeting therapeutic artificial miRNA suppresses the growth and invasion of breast cancer in vivo and in vitro.
Neoplasm Metastasis
MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Neoplasm Metastasis
MEKK2 regulates focal adhesion stability and motility in invasive breast cancer cells.
Neoplasm Metastasis
MEKK2 regulates paxillin ubiquitylation and localization in MDA-MB 231 breast cancer cells.
Neoplasm Metastasis
MEKK3 and survivin expression in cervical cancer: association with clinicopathological factors and prognosis.
Neoplasm Metastasis
Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
Neoplasm Metastasis
MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.
Neoplasm Metastasis
Mouse model for pre-clinical study of human cancer immunotherapy.
Neoplasm Metastasis
Multifocal gastric gastrointestinal stromal tumors (GISTs) with lymph node metastases in children and young adults: a comparative clinical and histomorphological study of three cases including a new case of Carney triad.
Neoplasm Metastasis
Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor.
Neoplasm Metastasis
New insight into BIRC3: A novel prognostic indicator and a potential therapeutic target for liver cancer.
Neoplasm Metastasis
Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer.
Neoplasm Metastasis
Oncogenic B-RAF(V600E) Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion.
Neoplasm Metastasis
Overexpression of MEKK2 is associated with colorectal carcinogenesis.
Neoplasm Metastasis
Overview of MDM2 and B-RAF Expression in Gastric Lesions.
Neoplasm Metastasis
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Neoplasm Metastasis
Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.
Neoplasm Metastasis
Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
Neoplasm Metastasis
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
Neoplasm Metastasis
Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.
HOME
login
history
all enzymes
BRENDA home
History
2.7.11.25 mitogen-activated protein kinase kinase kinase
more
top
